Generics - Teva Pharmaceutical Industries, Copaxone

Filter

Popular Filters

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

US Court rejects Teva’s Copaxone appeal

15-05-2014

A US district court has dismissed a case by Israeli drugmaker Teva Pharmaceutical Industries intended…

CopaxoneGenericsLegalMylanNeurologicalPatentsTeva Pharmaceutical IndustriesUSA

Teva files suit against US FDA over generic Copaxone

Teva files suit against US FDA over generic Copaxone

12-05-2014

Israel-based Teva Pharmaceutical Industries has complained to the US Food and Drug Administration that…

Business FinanceCopaxoneGenericsGlatiramer acetateHealth Medical PharmaLegalNeurologicalScience and technology in IsraelSocial IssuesTeva Pharmaceutical IndustriesUSA

US Supreme Court denies Teva's request for injunction relating to Mylan’s generic Copaxone

21-04-2014

The US Supreme Court Chief Justice Roberts has denied Israeli generics giant Teva Pharmaceutical Industries’…

CopaxoneGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaPatentsTeva Pharmaceutical IndustriesUSA

Natco prevails in Indian Copaxone patent dispute with Teva

Natco prevails in Indian Copaxone patent dispute with Teva

03-03-2014

Hyderabad, India-based Natco Pharma has won a significant patent battle against Israeli generics giant…

Asia-PacificCopaxoneGenericsIndiaNatco PharmaPatents & Trade marksTeva Pharmaceutical Industries

Teva’s full year results steady led by Copaxone sales up 8%

Teva’s full year results steady led by Copaxone sales up 8%

07-02-2014

Israel-based Teva Pharmaceutical Industries has released its full year results for 2014 showing that…

CopaxoneEastern EuropeFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

FT Pharma 2013: Teva’s acting CEO says it has “a very strong and clear strategy”

FT Pharma 2013: Teva’s acting CEO says it has “a very strong and clear strategy”

05-12-2013

Eyal Desheh, acting president and chief executive of the world’s largest generics maker Teva (NYSE:…

CopaxoneGenericsInterviewsManagementPharmaceuticalRest of the WorldTeva Pharmaceutical Industries

Teva Pharma sees slowdown in generic revenues

01-08-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), the world largest generics firm but with a…

CopaxoneFinancialGenericsPharmaceuticalTeva Pharmaceutical Industries

US Appeals Court overturns Copaxone patent decision

28-07-2013

Israel-based generics giant Teva Pharmaceutical Industries ((NYSE: TEVA) said on Friday (July 26) that…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaNovartisPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Court ruling favors Mylan in Copaxone patent dispute

17-07-2013

A US court has dismissed claims that US generic drugmaker Mylan (Nasdaq: MYL) infringed four patents…

CopaxoneGenericsMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsSandozTeva Pharmaceutical Industries

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

12-12-2012

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's…

CopaxoneFinancialGenericsLicensingPatentsPharmaceuticalResearchTeva Pharmaceutical IndustriesXenon Pharmaceuticals

Teva gets favorable UK Copaxone patent ruling

12-07-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the UK High Court of Justice issued…

CopaxoneEuropeGenericsLegalMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

Parexel

Parexel

Back to top